Leading commodity bourse MCX on Saturday posted a 12.56 per cent rise in its consolidated net profit to Rs 38.79 crore for the third quarter ended December 2022. Its net profit stood at Rs 34.46 crore during the same quarter of the previous fiscal, according to a regulatory filing. The company's total income rose on a consolidated basis to Rs 163.65 crore in the December 2022 quarter from Rs 104.06 crore in the year-ago period. MCX largely offers derivatives in the non-commodity segment.
The company's total income during the quarter was seen up by 17 per cent to Rs 3,622.62 crore, as against Rs 3,083.95 crore during the third quarter of 2021-22
The company's consolidated earnings before interest tax depreciation and amortisation (Ebitda) grew 53 per cent versus last year to Rs 3,816 crore
Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish
Bank management says, exposure to Adani Group well below the ceiling prescribed by RBI under large exposure framework
A healthy rise in NII and a sharp drop in credit costs boost bottom-line
Revenues from the non-cigarettes FMCG segment was at Rs 4,848.95 crore compared to Rs 4,099.47 crore
Record Rs 1,422-cr quarterly profit comes on the back of best-ever revenue
Growing global and domestic demand, better semiconductor chip supplies, and softening commodity prices are powering the automotive manufacturer's ride out of losses
Domestic business grows one per cent in the quarter; international by 7%
Revenue from operations increased by 0.8% to Rs 17,122.15 crore from Rs 16,971.18 crore in the previous fiscal quarter
Zydus Lifesciences Ltd on Friday reported a 24.48 per cent rise in consolidated net profit at Rs 622.9 crore for the third quarter ended December 31, 2022. The company had posted a consolidated net profit of Rs 500.4 crore in the same period last fiscal, Zydus Lifesciences Ltd said in a regulatory filing. Consolidated total revenue from operations during the quarter under review stood at Rs 4,362.3 crore, as against Rs 3,639.8 crore in the year-ago period, it added. Total expenses in the third quarter were higher at Rs 3,620.7 crore, as compared to Rs 3,096.3 crore in the corresponding period last fiscal. In the third quarter, its business in India comprising formulations as well as consumer wellness registered revenues of Rs 1,643.6 crore, up 13 per cent, while the US formulations business registered revenues of Rs 1,925 crore, up 29 per cent from the year-ago period, the company said. Emerging markets formulations business registered revenues of Rs 307.8 crore, up 15 per cent an
SBI Q3 result: The profit number beat Street estimate. Consensus estimates by Bloomberg had projected net profit at Rs 13,196 crore
Revenue rises 10%; company lines up Rs 1,600 cr plan to revamp old plants
Closing Bell: On the Nifty, Adani Ports closed in green after two days with a firm gain of 6 per cent., while Adani Enterprises erased over 50 per cent of its day's losses to close 2 per cent down
In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall in revenue
On the bourses, shares of the bank jumped over 5 per cent to an intra-day high of Rs 162.3 per share
Given strong execution, analysts at Emkay Global Financial Services, too, remain confident of the high-teens earnings trajectory for Titan in the medium term
Stocks to watch today: The National Stock Exchange (NSE) on Thursday shifted Adani Enterprises, Adani Ports, and Ambuja Cements to a category of stocks that require up to 100 per cent trading margins
Max Healthcare Institute on Thursday reported a 7 per cent increase in its consolidated profit after tax at Rs 269 crore for the December quarter. The healthcare provider had posted a profit after tax of Rs 252 crore in the October-December period of last fiscal. Network gross revenue increased to Rs 1,559 crore, reflecting a 13 per cent year-on-year growth, Max Healthcare said in a statement. "By virtue of focus on healthcare infrastructure, research and skilling as well as ground breaking policies such as National Digital Healthcare Mission, Heal In India and Heal By India, the government has established a solid foundation to enable the private sector players in India to cater to both domestic and global requirements at affordable prices," Max Healthcare Institute Chairman and MD Abhay said. Shares of the company ended 0.23 per cent down at Rs 440.4 apiece on the BSE.